Clinical trial · Observational
PARPi and Ovarian Cancer Survival
Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Ovarian Carcinoma | ALIAS | 0.85 |
| PARP Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Patients with newly diagnosed advanced epithelial ovarian cancer
- description
- Patients who were newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer between December 2013 and December 2024.
- label
- Patients with platinum-sensitive first relapsed epithelial ovarian cancer
- description
- Patients with platinum-sensitive first relapsed ovarian cancer who were diagnosed between December 2013 and December 2024
Primary outcomes (1)
- measure
- Overall Mortality
- timeFrame
- 11 years
- description
- Mortality of any cause
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Group 1: * Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024. * Complete data on first-line treatment and maintenance therapy. * Availability of follow-up data. Group 2: * Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024. * Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen. * Complete data on second-line treatment and maintenance therapy. * Availability of follow-up data. Exclusion Criteria: Group 1: * Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * Missing first-line or follow-up data. Group 2: * Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * Patients with second relapse. * Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy. * Missing second-line or follow-up data.
References
Publications (0)
Data not yet available